Preclinical Testing News and Research

RSS

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

AMSilk completes preclinical testing of proprietary silicone breast implant coating

AMSilk has completed preclinical testing of its proprietary silicone implant coating made from spider silk. AMSilk's coating consists of a thin layer of spider silk proteins manufactured by AMSilk.

29 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

The Jackson Laboratory, in collaboration with Seoul National University, will receive a five-year, $7.5 million grant from the South Korean government for a large-scale cancer genomics project employing the latest sequencing technology and special JAX mouse models that can host human tumors.

22 Jan 2014

LSDF announces research and development grants to commercialize health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced $1.1 million in five Proof of Concept grants to Washington for-profit and non-profit organizations to foster the translation of health-related products from the laboratory into the commercial marketplace.

19 Dec 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Moderna Therapeutics Scores Up To $25M DARPA Grant

...

2 Oct 2013

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.

13 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Scientists develop new chemo drug that fights cancer without impacting fertility

A new gentler chemotherapy drug in the form of nanoparticles has been designed by Northwestern Medicine- scientists to be less toxic to a young woman's fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.

25 Mar 2013

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex to target with a drug since it is also crucial to the healthy functioning of many immune cells in the body, not just B cells gone bad.

4 Mar 2013

New rehabilitation system improves QOL for people with brain damage

The Biomechanics Institute of Valencia (IBV) is currently taking part in the European project WALKX with the aim of developing an innovative rehabilitation system to improve the quality of life of people who have suffered brain damage. This system will allow home rehabilitation and improve patient's autonomy.

11 Jan 2013

Preclinical Testing News and Research

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

TSRI scientists design artificial proteins as a candidate vaccine against RSV

AMSilk completes preclinical testing of proprietary silicone breast implant coating

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

LSDF announces research and development grants to commercialize health-related technologies

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Moderna Therapeutics Scores Up To $25M DARPA Grant

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

ImmunoGen reports net loss of $21.9 million in Q4 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Scientists develop new chemo drug that fights cancer without impacting fertility

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

New rehabilitation system improves QOL for people with brain damage

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News